OpenEvidence(@OpenEvidence):Today, Memorial Sloan Kettering Cancer Center (MSK) and OpenEvidence announced a partnership to advance precision oncology. This partnership includes integration of OpenEvidence within MSK’s Epic workflow, and bringing OncoKB™, MSK's precision oncology knowledge base, directly into OpenEvidence for its broader use by physicians outside of @MSKCancerCenter. “AI has the potential to fundamentally change how we translate an increasingly complex and rapidly expanding body of knowledge into better decisions for patients,” – Anaeze Offodile, M.D., Chief Strategy Officer at MSK. Full press release:

2026.09.16 17:16

Today, Memorial Sloan Kettering Cancer Center (MSK) and OpenEvidence announced a partnership to advance precision oncology. This partnership includes integration of OpenEvidence within MSK’s Epic workflow, and bringing OncoKB™, MSK's precision oncology knowledge base, directly into OpenEvidence for its broader use by physicians outside of @MSKCancerCenter. “AI has the potential to fundamentally change how we translate an increasingly complex and rapidly expanding body of knowledge into better decisions for patients,” – Anaeze Offodile, M.D., Chief Strategy Officer at MSK. Full press release:

显示更多